CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 99 enrolled
Drug / intervention
GSK163090 1 mg +2 moredrug
Likely dose
GSK163090 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00896363
NCT00896363Phase 2Completed
CompareCT.gov

A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of GSK163090 in Subjects With Major Depressive Disorder

GlaxoSmithKline·interventional·Posted May 11, 2009·Updated Mar 19, 2018

In Brief

A Phase 2 clinical trial evaluating GSK163090 1 mg, GSK163090 Placebo, and 1 other intervention for Depressive Disorder. Completed, enrolled 99 participants across 15 sites.

Detailed Summary

The purpose of this study is to test if GSK163090 can reduce the symptoms of depression. The safety and how well the body can handle the drug will also be investigated. The study will be conducted in Russia in hospitalised patients with severe depression. GSK163090 will be compared with placebo, which looks like the study drug but does not contain any active substance. Subjects will be given either the study drug or the matching placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder
CountriesRussia
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 11, 2009
Enrollment StartApr 23, 2009
Primary CompletionFeb 9, 2010
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 17.1 years ago

Interventions

GSK163090 1 mgdrug

Developed for the treatment of Major Depressive Disorder

GSK163090 Placebodrug

Developed for the treatment of Major Depressive Disorder

GSK163090 3 mgdrug

Developed for the treatment of Major Depressive Disorder